THE ONLY LIQUID FORM OF TAMOXIFEN.
SOLTAMOX is a prescription medicine used:
- to treat adults with estrogen receptor-positive breast cancer that has spread to other parts of the body (metastatic)
- to treat adults with early stage estrogen receptor-positive breast cancer after surgery and radiation for breast cancer
- to reduce the chance of developing breast cancer in the other breast in adults after surgery and radiation for breast cancer
- to reduce the risk of invasive breast cancer in adult women with DCIS, after breast surgery and radiation treatment
- to reduce the risk of getting breast cancer in women with a high risk of getting breast cancer
Ask your doctor about SOLTAMOX® (tamoxifen citrate) oral solution to see if it’s right for you.
- Same indications, side-effects, and safety profile as tamoxifen tablets
- Colorless, gluten-free, lactose-free, sugar-free liquid
- Licorice flavor
- 20mg dose of SOLTAMOX is administered as 10mL (equivalent to 2 teaspoons) of the oral solution
WARNING: UTERINE MALIGNANCIES and THROMBOEMBOLIC EVENTS
See full prescribing information for complete boxed warning.
- Serious, life-threatening, and fatal events from use of tamoxifen include uterine malignancies, stroke, and pulmonary embolism. (5.1, 5.2)
- Discuss risks and benefits of tamoxifen with women at high risk for breast cancer and women with ductal carcinoma in situ (DCIS) when considering tamoxifen use to reduce the risk of developing breast cancer. (5.1, 5.2)
- For most patients already diagnosed with breast cancer, the benefits of tamoxifen outweigh its risks. (5.1, 5.2)
SOLTAMOX® Important Safety Information
- Tamoxifen citrate is contraindicated in patients who require concomitant warfarin therapy, or a
history of deep vein thrombosis or pulmonary embolus, and in patients with known hypersensitivity
to the drug or any of its ingredients.
- Uterine malignancies: Promptly evaluate abnormal vaginal bleeding in a woman with current or
past tamoxifen use.
- Thromboembolic events: Risk increases with coadministered chemotherapy. For treatment of
breast cancer, consider risks and benefits in patients with a history of thromboembolic events.
- Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the
potential risk to a fetus and to use effective contraception.
- Effects on the liver: Liver cancer and liver abnormalities, some fatal, have occurred. Perform
periodic liver function testing.
- The most common adverse reactions (≥20% incidence) associated with tamoxifen are hot flashes,
mood disturbances, vaginal discharge, vaginal bleeding, nausea, and fluid retention.
- Anastrozole and letrozole: Should not be used in combination with tamoxifen.
- Warfarin: Do not use in patients taking tamoxifen for DCIS and for reduction in breast cancer
incidence in women at high risk. Closely monitor coagulation indices for increased anticoagulant
effect when used with tamoxifen for metastatic breast cancer or as adjuvant therapy.
- Do not use tamoxifen in lactating women.
- Verify pregnancy status of females prior to initiation of tamoxifen.
- Advise females and males to use effective contraception.
Please see full Prescribing Information for SOLTAMOX.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.